Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.

BioMed research international - 1 Jan 2015

Liu Chien-Ming, Chiu Kuo-Liang, Chen Tzu-Sheng, Chang Shang-Miao, Yang Shu-Yun, Chen Li-Hsiou, Ni Yung-Lun, Sher Yuh-Pyng, Yu Sung-Liang, Ma Wen-Lung

Abstract excerpt

INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations are known as oncogene driver mutations and with EGFR mutations exhibit good response to the EGFR tyrosine kinase inhibitor Gefitinib. Some studies have shown that activation of estrogen and estrogen receptor α or β (ERα/β) promote adenocarcinoma. We evaluated the relationship between the two receptors and the potential therapeutic benefit with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Estrogen Receptor alpha

Share to Estrogen Receptor beta

Share to Gefitinib

Share to Quinazolines

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 25692143
DOI: 10.1155/2015/642041
PMCID: PMC4321093

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.PMID 25692143Read ↗

ERβ1 Expression Patterns Have Different Effects On EGFR TKIs Treatment Response in EGFR Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung.Semantic proximity Read ↗

Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma.Semantic proximity Read ↗

The Crosstalk Mechanism of EGFR and ER in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients.Semantic proximity Read ↗

Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.Semantic proximity Read ↗

Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung.Semantic proximity Read ↗

mPRα mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.Semantic proximity Read ↗

Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.Semantic proximity Read ↗

Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.Semantic proximity Read ↗

Lack of direct association between EGFR mutations and ER beta expression in lung cancer.Semantic proximity Read ↗

ERβ regulates NSCLC phenotypes by controlling oncogenic RAS signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.